Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences.
- The Morgan Stanley 19th Annual Global Healthcare Conference – The fireside chat will take place on Thursday, September 9, 2021 at 11:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., and Chief Financial Officer John Crowley.
- The H.C. Wainwright 23rd Annual Global Investment Conference – A recording of the presentation will be made available for on-demand viewing on Monday, September 13, at 7:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
Webcasts of each event will be available on the “Events and Presentations” page in the “Investors & Media” section of the Company’s website at https://ir.fusionpharma.com/events-webcasts. Replays of the webcasts will be archived on the Company’s website for 90 days following their respective presentation dates.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and AstraZeneca’s DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company’s growing pipeline of TATs.
SOURCE Fusion Pharmaceuticals Inc.